All In Biotech

Drug Trial Radar · NCT06532656

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 20, 2024

Primary completion

Jul 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn about the safety and tolerability of bictegravir (BIC)/lenacapavir (LEN) and to learn how the study drug interacts with the body in virologically suppressed (VS) children and adolescents with human immunodeficiency virus type 1 (HIV-1) on a stable and complex antiretroviral (ARV) regimen. The study will also assess the safe loading dose of LEN and pharmacokinetics (PK) of BIC/LEN. The primary objectives of this study are: * To evaluate the steady-state PK of BIC and LEN and confirm the dose of the LEN loading dose and BIC/LEN FDC in VS children and adolescents with HIV-1. * To evaluate the safety and tolerability of BIC/LEN through Week 24 in VS children and adolescents with HIV-1.

Conditions

  • HIV-1-infection

Interventions

  • LenacapavirDrug

    Tablets administered orally without regard to food

  • Bictegravir/Lenacapavir (BIC/LEN) FDCDrug

    Tablets administered orally without regard to food

  • Bictegravir/LenacapavirDrug

    Tablets administered orally without regard to food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK Parameter: Cmax of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
  2. PK Parameter: AUCtau of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
  3. PK Parameter: Ctrough of BIC and LEN at Steady StateTime frame: Day 1 up to Week 24, as appropriate
  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24Time frame: First dose date up to Week 24
  5. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 24Time frame: First dose date up to Week 24

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's National Hospital

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Grady Ponce de Leon Center

    Atlanta, Georgia

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Helios Salud S.A

    Buenos Aires, Argentina

  • ASST FBF Sacco Ospedale Sacco

    Milan, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesu, UOS Infezioni Complesse e Perinatali

    Roma, Italy

  • FAMCRU Ukwanda School for Rural Health

    Cape Town, South Africa

  • Be Part Yoluntu

    Cape Town, South Africa

  • Durban International Clinical Research Site, Enhancing Care Foundation

    Durban, South Africa

  • Monti Clinical Research Centre

    East London, South Africa

  • Perinatal HIV Research Unit

    Johannesburg, South Africa

  • Wits RHI Shandukani Research Centre CRS

    Johannesburg, South Africa

  • Nkanyezi VIDA Research Unit

    Johannesburg, South Africa

  • Khomanani Health Research and Wellness Centre

    Ka-Majosi, South Africa

  • Clinical Research Institute of South Africa (CRISA)

    KwaDukuza, South Africa

  • The Aurum Institute: Pretoria Clinical Research Centre

    Pretoria, South Africa

  • Setshaba Research Centre

    Soshanguve, South Africa

  • Hospital General Universitario Gregorio Marano

    Madrid, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.